Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study

Fabiana Piscitelli, Roberto Coccurello, Antonio Totaro, Alessandro Leuti, Giacomo Giacovazzo, Roberta Verde, Emanuela Rossi, Michele Podaliri Vulpiani, Nicola Ferri, Roberto Giacominelli Stuffler, Vincenzo Di Marzo, Sergio Oddi, Tiziana Bisogno, Mauro Maccarrone

Research output: Contribution to journalArticle

Abstract

In the present work, mice overexpressing mutant amyloid precursor protein (Tg2576), a transgenic model of Alzheimer's disease (AD), are used to investigate a specific lipid profile over the course of disease progression. Using a targeted lipidomic approach, plasma levels of N-acylethanolamines with different length and unsaturation at presymptomatic, mild-symptomatic, and symptomatic disease stages are measured. Moreover, N-acylethanolamines are also assessed in the brain areas most affected in AD. The ethanolamides of palmitic, oleic, arachidonic, eicosapentaenoic, and docosahexaenoic acids do not show any significant alteration in blood of Tg2576 mice at the different stages analyzed, as compared to wild-type. Except for N-docosahexaenoylethanolamine, a general tendency to decrease is instead detected for all measured N-acylethanolamines in the cortex, hippocampus, striatum, and cerebellum of symptomatic Tg2576 mice. Together, the data can help to redefine the range of lipid-associated signals in Alzheimer pathophysiology. Practical Application: The development of novel therapies for AD is strongly narrowed not only by the lack of a full comprehension of underlying pathophysiological mechanisms but also by the absence of affordable, reliable, and noninvasive biomarkers. Hence, there is the practical necessity to acquire accessible blood biomarkers to provide rapid, cost-effective, and critical information to timely identify disease stage and implement preventive strategies aimed at slowing down cognitive decline. In this study, a targeted lipidomics investigation of N-acylethanolamines at different stages of disease progression, clearly indicates that the discovery of innovative blood biomarkers should be refocused on different indices of deranged lipid metabolism for a realistic prediction of the risk of AD. It is investigated that potential alterations of N-acylethanolamines content during disease development in a transgenic mouse model of Alzheimer's disease (AD). Circulating and central N-acylethanolamine levels did not show any alteration in Tg2576 mice at different disease stages.

Original languageEnglish
Article number1900015
JournalEuropean Journal of Lipid Science and Technology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Alzheimer disease
longitudinal studies
Transgenic Mice
Longitudinal Studies
Alzheimer Disease
animal models
genetically modified organisms
biomarkers
mice
disease course
Biomarkers
blood
Disease Progression
Lipids
Blood
cerebellum
amyloid
hippocampus
lipids
eicosapentaenoic acid

Keywords

  • Alzheimer's disease
  • lipidomics
  • N-acylethanolamines
  • Tg2576 mice

ASJC Scopus subject areas

  • Biotechnology
  • Food Science
  • Chemistry(all)
  • Industrial and Manufacturing Engineering

Cite this

Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD : A Longitudinal Study. / Piscitelli, Fabiana; Coccurello, Roberto; Totaro, Antonio; Leuti, Alessandro; Giacovazzo, Giacomo; Verde, Roberta; Rossi, Emanuela; Podaliri Vulpiani, Michele; Ferri, Nicola; Giacominelli Stuffler, Roberto; Di Marzo, Vincenzo; Oddi, Sergio; Bisogno, Tiziana; Maccarrone, Mauro.

In: European Journal of Lipid Science and Technology, 01.01.2019.

Research output: Contribution to journalArticle

Piscitelli, Fabiana ; Coccurello, Roberto ; Totaro, Antonio ; Leuti, Alessandro ; Giacovazzo, Giacomo ; Verde, Roberta ; Rossi, Emanuela ; Podaliri Vulpiani, Michele ; Ferri, Nicola ; Giacominelli Stuffler, Roberto ; Di Marzo, Vincenzo ; Oddi, Sergio ; Bisogno, Tiziana ; Maccarrone, Mauro. / Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD : A Longitudinal Study. In: European Journal of Lipid Science and Technology. 2019.
@article{fff91248a9774f47ab0829809bccdcaa,
title = "Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study",
abstract = "In the present work, mice overexpressing mutant amyloid precursor protein (Tg2576), a transgenic model of Alzheimer's disease (AD), are used to investigate a specific lipid profile over the course of disease progression. Using a targeted lipidomic approach, plasma levels of N-acylethanolamines with different length and unsaturation at presymptomatic, mild-symptomatic, and symptomatic disease stages are measured. Moreover, N-acylethanolamines are also assessed in the brain areas most affected in AD. The ethanolamides of palmitic, oleic, arachidonic, eicosapentaenoic, and docosahexaenoic acids do not show any significant alteration in blood of Tg2576 mice at the different stages analyzed, as compared to wild-type. Except for N-docosahexaenoylethanolamine, a general tendency to decrease is instead detected for all measured N-acylethanolamines in the cortex, hippocampus, striatum, and cerebellum of symptomatic Tg2576 mice. Together, the data can help to redefine the range of lipid-associated signals in Alzheimer pathophysiology. Practical Application: The development of novel therapies for AD is strongly narrowed not only by the lack of a full comprehension of underlying pathophysiological mechanisms but also by the absence of affordable, reliable, and noninvasive biomarkers. Hence, there is the practical necessity to acquire accessible blood biomarkers to provide rapid, cost-effective, and critical information to timely identify disease stage and implement preventive strategies aimed at slowing down cognitive decline. In this study, a targeted lipidomics investigation of N-acylethanolamines at different stages of disease progression, clearly indicates that the discovery of innovative blood biomarkers should be refocused on different indices of deranged lipid metabolism for a realistic prediction of the risk of AD. It is investigated that potential alterations of N-acylethanolamines content during disease development in a transgenic mouse model of Alzheimer's disease (AD). Circulating and central N-acylethanolamine levels did not show any alteration in Tg2576 mice at different disease stages.",
keywords = "Alzheimer's disease, lipidomics, N-acylethanolamines, Tg2576 mice",
author = "Fabiana Piscitelli and Roberto Coccurello and Antonio Totaro and Alessandro Leuti and Giacomo Giacovazzo and Roberta Verde and Emanuela Rossi and {Podaliri Vulpiani}, Michele and Nicola Ferri and {Giacominelli Stuffler}, Roberto and {Di Marzo}, Vincenzo and Sergio Oddi and Tiziana Bisogno and Mauro Maccarrone",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ejlt.201900015",
language = "English",
journal = "European Journal of Lipid Science and Technology",
issn = "1438-7697",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD

T2 - A Longitudinal Study

AU - Piscitelli, Fabiana

AU - Coccurello, Roberto

AU - Totaro, Antonio

AU - Leuti, Alessandro

AU - Giacovazzo, Giacomo

AU - Verde, Roberta

AU - Rossi, Emanuela

AU - Podaliri Vulpiani, Michele

AU - Ferri, Nicola

AU - Giacominelli Stuffler, Roberto

AU - Di Marzo, Vincenzo

AU - Oddi, Sergio

AU - Bisogno, Tiziana

AU - Maccarrone, Mauro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the present work, mice overexpressing mutant amyloid precursor protein (Tg2576), a transgenic model of Alzheimer's disease (AD), are used to investigate a specific lipid profile over the course of disease progression. Using a targeted lipidomic approach, plasma levels of N-acylethanolamines with different length and unsaturation at presymptomatic, mild-symptomatic, and symptomatic disease stages are measured. Moreover, N-acylethanolamines are also assessed in the brain areas most affected in AD. The ethanolamides of palmitic, oleic, arachidonic, eicosapentaenoic, and docosahexaenoic acids do not show any significant alteration in blood of Tg2576 mice at the different stages analyzed, as compared to wild-type. Except for N-docosahexaenoylethanolamine, a general tendency to decrease is instead detected for all measured N-acylethanolamines in the cortex, hippocampus, striatum, and cerebellum of symptomatic Tg2576 mice. Together, the data can help to redefine the range of lipid-associated signals in Alzheimer pathophysiology. Practical Application: The development of novel therapies for AD is strongly narrowed not only by the lack of a full comprehension of underlying pathophysiological mechanisms but also by the absence of affordable, reliable, and noninvasive biomarkers. Hence, there is the practical necessity to acquire accessible blood biomarkers to provide rapid, cost-effective, and critical information to timely identify disease stage and implement preventive strategies aimed at slowing down cognitive decline. In this study, a targeted lipidomics investigation of N-acylethanolamines at different stages of disease progression, clearly indicates that the discovery of innovative blood biomarkers should be refocused on different indices of deranged lipid metabolism for a realistic prediction of the risk of AD. It is investigated that potential alterations of N-acylethanolamines content during disease development in a transgenic mouse model of Alzheimer's disease (AD). Circulating and central N-acylethanolamine levels did not show any alteration in Tg2576 mice at different disease stages.

AB - In the present work, mice overexpressing mutant amyloid precursor protein (Tg2576), a transgenic model of Alzheimer's disease (AD), are used to investigate a specific lipid profile over the course of disease progression. Using a targeted lipidomic approach, plasma levels of N-acylethanolamines with different length and unsaturation at presymptomatic, mild-symptomatic, and symptomatic disease stages are measured. Moreover, N-acylethanolamines are also assessed in the brain areas most affected in AD. The ethanolamides of palmitic, oleic, arachidonic, eicosapentaenoic, and docosahexaenoic acids do not show any significant alteration in blood of Tg2576 mice at the different stages analyzed, as compared to wild-type. Except for N-docosahexaenoylethanolamine, a general tendency to decrease is instead detected for all measured N-acylethanolamines in the cortex, hippocampus, striatum, and cerebellum of symptomatic Tg2576 mice. Together, the data can help to redefine the range of lipid-associated signals in Alzheimer pathophysiology. Practical Application: The development of novel therapies for AD is strongly narrowed not only by the lack of a full comprehension of underlying pathophysiological mechanisms but also by the absence of affordable, reliable, and noninvasive biomarkers. Hence, there is the practical necessity to acquire accessible blood biomarkers to provide rapid, cost-effective, and critical information to timely identify disease stage and implement preventive strategies aimed at slowing down cognitive decline. In this study, a targeted lipidomics investigation of N-acylethanolamines at different stages of disease progression, clearly indicates that the discovery of innovative blood biomarkers should be refocused on different indices of deranged lipid metabolism for a realistic prediction of the risk of AD. It is investigated that potential alterations of N-acylethanolamines content during disease development in a transgenic mouse model of Alzheimer's disease (AD). Circulating and central N-acylethanolamine levels did not show any alteration in Tg2576 mice at different disease stages.

KW - Alzheimer's disease

KW - lipidomics

KW - N-acylethanolamines

KW - Tg2576 mice

UR - http://www.scopus.com/inward/record.url?scp=85070067079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070067079&partnerID=8YFLogxK

U2 - 10.1002/ejlt.201900015

DO - 10.1002/ejlt.201900015

M3 - Article

AN - SCOPUS:85070067079

JO - European Journal of Lipid Science and Technology

JF - European Journal of Lipid Science and Technology

SN - 1438-7697

M1 - 1900015

ER -